Pasithea shareholders approve 2023 equity plan and reverse split authorization

Pasithea Therapeutics Corp.

Stockholders approved Pasithea 2023 Stock Incentive Plan: 2.5M shares reserved plus rollover of unused 2021 plan shares.
Reverse stock split authorized (1:2 to 1:20) at Board discretion within one year; corresponding reduction in authorized shares allowed.
All five director nominees elected: Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy, Alfred Novak.
Marcum LLP ratified as independent auditor for FY 2023; annual meeting partially adjourned to Dec. 28 for additional governance proposals.
Proxies remain open only for adjourned proposals (charter amendment, classified board, written consent restrictions).

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pasithea Therapeutics Corp. shareholders approved Amendment to Certificate of Incorporation to effect a reverse stock split at a specific ratio ranging from one-for-two to one-for-twenty at the 2023-12-19 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-12-19

Exact text from the filing

FOR AGAINST ABSTAIN BROKER NON-VOTES 13,432,469 1,181,664 156,671 N/A

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pasithea Therapeutics Corp. shareholders approved Approval of the Pasithea Therapeutics Corp. 2023 Stock Incentive Plan at the 2023-12-19 meeting.

Proposal: equity plan
Outcome: passed
Meeting: 2023-12-19

Exact text from the filing

FOR AGAINST ABSTAIN BROKER NON-VOTES 9,196,502 1,520,422 987,467 3,066,413

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pasithea Therapeutics Corp. shareholders approved Election of each of Dr. Tiago Reis Marques, Prof. Lawrence Steinman, Simon Dumesnil, Dr. Emer Leahy and Alfred Novak at the 2023-12-19 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-12-19

Exact text from the filing

The appointment of each of the foregoing directors was approved by a plurality of the votes cast at the Annual Meeting as follows: FOR WITHHELD BROKER NON-VOTES Dr. Tiago Reis Marques 11,433,844 270,547 3,066,413 Prof. Lawrence Steinman 11,434,292 270,099 3,066,413 Simon Dumesnil 11,409,027 295,364 3,066,413 Dr. Emer Leahy 11,408,775 295,616 3,066,413 Alfred Novak 11,369,003 335,388 3,066,413

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Pasithea Therapeutics Corp. shareholders approved Ratification of appointment of Marcum LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-12-19 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-12-19

Exact text from the filing

FOR AGAINST ABSTAIN BROKER NON-VOTES 13,742,119 992,581 36,104 N/A

View on SEC.gov

448 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-23-097013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.